A Phase 2 interventional study of PSMA-radioguided surgery and ADT in Prostate Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by The Netherlands Cancer Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute — 6 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · The Netherlands Cancer Institute.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 10th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 13 interventional studies, 26 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.
1 of the studies in Prostatic Neoplasms by The Netherlands Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07391982The Netherlands Cancer InstituteDose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ADT with or without robot-assisted PSMA-radioguided surgery for patients with recurrent prostate cancer.
Improving the oncological treatment outcomes in men with a biochemical recurrence after primary prostate cancer (PC) treatment that are diagnosed with a disease recurrence confined to the regional lymph nodes or local residual disease using Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography and Computed Tomography (PET/CT.)
The proposed trial randomizes patients with recurrent PC following primary PC treatment to either 6 months of ADT or Technetium-PSMA-radioguided salvage surgery plus 6 months of ADT. Although the optimal duration of ADT is unknown, a minimal duration of 6 months of ADT seems advisable in this setting and will be mandatory for both arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in arm A will receive standard 6 months of ADT according to current clinical guidelines.
Drug: ADT
Patients in arm B will receive standard 6 months of ADT according to current clinical guidelines, and will undergo 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.
Procedure: PSMA-radioguided surgery · Drug: ADT
Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
Clinical progression-free survival (CPFS)
CPFS is defined as time between randomization and the appearance of a recurrence (any N1 or M1) as suggested by PSMA PET/CT or symptoms related to progressive PC, or death due to any cause
Time frame: 24 months
Metastasis-free survival (MFS)
Metastasis-free survival will be defined as the time between randomization and the appearance of a metastatic recurrence (any M1) as suggested by PSMA PET-CT.
Time frame: 24 months
Biochemical progression-free survival (BPFS)
Biochemical progression-free survival will be defined as the time between randomization and the development of biochemical progression ( three consecutive rises in prostate specific antigen (PSA) 1 week apart, resulting in two 50% increases over the nadir and PSA\>2 ng/ml)
Time frame: 24 months
Castrate resistant prostate cancer (CRPC)
CRPC is defined as castrate serum testosterone\<50 ng/dl plus biochemical progression, i.e., three consecutive rises in PSA 1 week apart, resulting in two 50% increases over the nadir and PSA\>2 ng/ml.
Time frame: 10 years
Overall survival (OS)
Overall survival will be read as the time from trial randomization to the date of death from any cause
Time frame: 10 years
Incidence of adjuvant therapy
ADT, radiation therapy or additional salvage surgery
Time frame: 10 years
Patient reported QOL as per EORTC-QLQ C30
Quality of life (QoL) will be assessed with the EORTC Core Quality of Life questionnaire's (QLQ-C30) global QoL scale ranging from 0 to 100, higher scores indicate better QoL
Time frame: 24 months
Patient reported QOL as per Expanded Prostate cancer Index Composite (EPIC) 26
Quality of life (QoL) will be assessed with the EPIC 26 questionnaire, containing 26 items covering 5 domains: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better QOL.
Time frame: 24 months
Complications
Assessment of 99mTc-PSMA-I\&S injection-related as well as surgery-related complication rate according to Clavien-Dindo.
Time frame: 30 and 90 days
Number of in-field recurrences
Recurrence measured by use of PSMA PET/CT in the template of 99mTc-PSMA-radioguided surgery (RGS) supported salvage surgery
Time frame: 24 months
Specificity of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation
In percentage
Time frame: 30 days
Sensitivity of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation
In percentage
Time frame: 30 days
Positive Predictive Value of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation
In percentage
Time frame: 30 days
Negative Predictive Value of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation
In percentage
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Nov 2024, 21 months after the start.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 21 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Netherlands Cancer Institute →